Edition:
India

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

1.47USD
22 Mar 2019
Change (% chg)

$-0.01 (-0.68%)
Prev Close
$1.48
Open
$1.46
Day's High
$1.48
Day's Low
$1.37
Volume
83,288
Avg. Vol
71,839
52-wk High
$3.15
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

TRACON Pharmaceuticals Presents Positive Top-Line Clinical Data From Dose Escalation Portion Of Phase 1 Trial Of TRC105 And Opdivo For Treatment Of Non-Small Cell Lung Cancer
Thursday, 27 Dec 2018 

Dec 26 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS PRESENTS POSITIVE TOP-LINE CLINICAL DATA FROM DOSE ESCALATION PORTION OF PHASE 1 TRIAL OF TRC105 AND OPDIVO® FOR TREATMENT OF NON-SMALL CELL LUNG CANCER.TRACON - COMBINATION OF TRC105 & OPDIVO WELL-TOLERATED WITHOUT DEVELOPMENT OF DOSE LIMITING TOXICITY IN 6 PATIENTS TREATED AS PART OF DOSE ESCALATION.TRACON PHARMACEUTICALS INC - EXPECT TO PRESENT DATA FROM EXPANSION COHORTS IN MID-2019.  Full Article

Tracon Pharmaceuticals, I-Mab Biopharma Announce Strategic Partnerships For Multiple Immuno-Oncology Programs
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS AND I-MAB BIOPHARMA ANNOUNCE STRATEGIC PARTNERSHIPS FOR MULTIPLE IMMUNO-ONCOLOGY PROGRAMS.TRACON AND I-MAB ENTERED INTO A COST-SHARING PRODUCT DEVELOPMENT COLLABORATION.TRACON - CO WILL BEAR COSTS OF EARLY PHASES OF CLINICAL TRIALS AND I-MAB WILL SHARE COSTS FOR MORE ADVANCED DEVELOPMENT STAGES, COMMERCIALIZATION.  Full Article

Tracon Pharmaceuticals Inc Quarterly Earnings Per Share $0.33
Thursday, 9 Aug 2018 

TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.TRACON PHARMACEUTICALS INC QUARTERLY EARNINGS PER SHARE $0.33.  Full Article

Tracon Pharmaceuticals CEO Charles Theuer Appointed As Principal Financial Officer
Saturday, 16 Jun 2018 

June 15 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS - EFFECTIVE UPON PATRICIA BITAR'S RESIGNATION, CHARLES P. THEUER, CO'S CEO, WAS APPOINTED AS PRINCIPAL FINANCIAL OFFICER.  Full Article

Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Tracon Pharmaceuticals Inc ::AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA.AMBRX INC - ENTERED INTO LICENSING AGREEMENT FOR DEVELOPMENT & COMMERCIALIZATION OF TRACON'S PROPRIETARY ENDOGLIN ANTIBODY, TRC105 IN CHINA.AMBRX SAYS TRANSACTION GRANTS AMBRX EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE TRC105 IN ALL INDICATIONS IN CHINA AND TAIWAN.AMBRX SAYS UNDER DEAL TERMS, TRACON WILL RECEIVE AN UPFRONT PAYMENT OF $3 MILLION.AMBRX SAYS TRACON IS ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES FROM HIGH SINGLE DIGITS TO LOW TEENS ON NET SALES OF TRC105 IN AMBRX TERRITORIES.  Full Article

Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Tracon Pharmaceuticals Inc ::Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget.Tracon Pharmaceuticals -‍in trial, 4 of 17 patients experienced partial response to treatment, eight additional patients (8/17, 47%) had stable disease​.Tracon Pharmaceuticals -‍in trial, combination of trc102,fludara produced evidence of tumor DNA damage that appeared to correlate with antitumor activity​.  Full Article

Tracon Pharma reports third quarter financial results
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals reports third quarter financial results and provides corporate update.Tracon Pharmaceuticals Inc-qtrly ‍shr $0.07​.  Full Article